1. Home
  2. NEXA vs ABUS Comparison

NEXA vs ABUS Comparison

Compare NEXA & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEXA
  • ABUS
  • Stock Information
  • Founded
  • NEXA 1956
  • ABUS 2005
  • Country
  • NEXA Luxembourg
  • ABUS United States
  • Employees
  • NEXA N/A
  • ABUS N/A
  • Industry
  • NEXA Metal Mining
  • ABUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • NEXA Basic Materials
  • ABUS Health Care
  • Exchange
  • NEXA Nasdaq
  • ABUS Nasdaq
  • Market Cap
  • NEXA 646.3M
  • ABUS 711.2M
  • IPO Year
  • NEXA 2017
  • ABUS N/A
  • Fundamental
  • Price
  • NEXA $4.93
  • ABUS $4.42
  • Analyst Decision
  • NEXA Sell
  • ABUS Strong Buy
  • Analyst Count
  • NEXA 4
  • ABUS 2
  • Target Price
  • NEXA $5.25
  • ABUS $5.00
  • AVG Volume (30 Days)
  • NEXA 29.7K
  • ABUS 1.6M
  • Earning Date
  • NEXA 10-30-2025
  • ABUS 11-05-2025
  • Dividend Yield
  • NEXA 2.02%
  • ABUS N/A
  • EPS Growth
  • NEXA N/A
  • ABUS N/A
  • EPS
  • NEXA N/A
  • ABUS N/A
  • Revenue
  • NEXA $2,785,931,000.00
  • ABUS $15,416,000.00
  • Revenue This Year
  • NEXA N/A
  • ABUS $138.02
  • Revenue Next Year
  • NEXA $4.01
  • ABUS N/A
  • P/E Ratio
  • NEXA N/A
  • ABUS N/A
  • Revenue Growth
  • NEXA 7.34
  • ABUS 53.23
  • 52 Week Low
  • NEXA $4.44
  • ABUS $2.71
  • 52 Week High
  • NEXA $9.61
  • ABUS $5.10
  • Technical
  • Relative Strength Index (RSI)
  • NEXA 50.13
  • ABUS 63.43
  • Support Level
  • NEXA $4.83
  • ABUS $4.37
  • Resistance Level
  • NEXA $5.39
  • ABUS $5.10
  • Average True Range (ATR)
  • NEXA 0.19
  • ABUS 0.27
  • MACD
  • NEXA 0.02
  • ABUS 0.02
  • Stochastic Oscillator
  • NEXA 23.21
  • ABUS 53.10

About NEXA Nexa Resources S.A.

Nexa Resources SA is a low-cost integrated zinc producer. It produces copper, silver, and gold as byproducts. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: